Secretion of ofloxacin into saliva in patients with respiratory tract infection

K. Takagi, T. Hasegawa, K. Yamaki, K. Suzuki, Toshitaka Nabeshima

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

The simultaneous saliva and plasma ofloxacin (OFLX) concentrations in patients with respiratory tract infection were measured by a microbiological agar-well diffusion assay following a single oral administration of an OFLX preparation. The maximum concentration (C(max)), the time to reach that peak (t(max)) and the elimination half-life of OFLX derived from salivary concentration data were 5.2 ± 0.4 mg/l, 1.9 ± 0.4 h and 3.6 ± 0.5 h, respectively, which were in agreement with those derived from plasma concentration data. The mean saliva-to-plasma concentration ratio (C(s)/C(p)) obtained after the administration of a single oral dose was 1.08 ± 0.05. This was both time-independent and concentration-independent, and it showed a certain relationship with age. A significant correlation was obtained between plasma and saliva concentrations (r = 0.768, p < 0.01). The coefficient of variation for the overall variability was approximately 30.0%. The present results indicate that the secretion of OFLX into saliva may be, at least, due to a passive diffusion mechanism, but a measurement of OFLX concentration in saliva as a guide to dose adjustment would be too wide at odds with plasma concentration to form the basis for a clinical decision.

Original languageEnglish
Pages (from-to)46-50
Number of pages5
JournalInternational Journal of Clinical Pharmacology Therapy and Toxicology
Volume30
Issue number2
Publication statusPublished - 01-01-1992
Externally publishedYes

Fingerprint

Ofloxacin
Saliva
Respiratory Tract Infections
Plasmas
Agar
Oral Administration
Half-Life
Assays

All Science Journal Classification (ASJC) codes

  • Toxicology
  • Pharmacology (medical)

Cite this

@article{7f496134a8c240daba3dfcfaccfb13d0,
title = "Secretion of ofloxacin into saliva in patients with respiratory tract infection",
abstract = "The simultaneous saliva and plasma ofloxacin (OFLX) concentrations in patients with respiratory tract infection were measured by a microbiological agar-well diffusion assay following a single oral administration of an OFLX preparation. The maximum concentration (C(max)), the time to reach that peak (t(max)) and the elimination half-life of OFLX derived from salivary concentration data were 5.2 ± 0.4 mg/l, 1.9 ± 0.4 h and 3.6 ± 0.5 h, respectively, which were in agreement with those derived from plasma concentration data. The mean saliva-to-plasma concentration ratio (C(s)/C(p)) obtained after the administration of a single oral dose was 1.08 ± 0.05. This was both time-independent and concentration-independent, and it showed a certain relationship with age. A significant correlation was obtained between plasma and saliva concentrations (r = 0.768, p < 0.01). The coefficient of variation for the overall variability was approximately 30.0{\%}. The present results indicate that the secretion of OFLX into saliva may be, at least, due to a passive diffusion mechanism, but a measurement of OFLX concentration in saliva as a guide to dose adjustment would be too wide at odds with plasma concentration to form the basis for a clinical decision.",
author = "K. Takagi and T. Hasegawa and K. Yamaki and K. Suzuki and Toshitaka Nabeshima",
year = "1992",
month = "1",
day = "1",
language = "English",
volume = "30",
pages = "46--50",
journal = "International Journal of Clinical Pharmacology and Therapeutics",
issn = "0946-1965",
publisher = "Dustri-Verlag Dr. Karl Feistle",
number = "2",

}

Secretion of ofloxacin into saliva in patients with respiratory tract infection. / Takagi, K.; Hasegawa, T.; Yamaki, K.; Suzuki, K.; Nabeshima, Toshitaka.

In: International Journal of Clinical Pharmacology Therapy and Toxicology, Vol. 30, No. 2, 01.01.1992, p. 46-50.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Secretion of ofloxacin into saliva in patients with respiratory tract infection

AU - Takagi, K.

AU - Hasegawa, T.

AU - Yamaki, K.

AU - Suzuki, K.

AU - Nabeshima, Toshitaka

PY - 1992/1/1

Y1 - 1992/1/1

N2 - The simultaneous saliva and plasma ofloxacin (OFLX) concentrations in patients with respiratory tract infection were measured by a microbiological agar-well diffusion assay following a single oral administration of an OFLX preparation. The maximum concentration (C(max)), the time to reach that peak (t(max)) and the elimination half-life of OFLX derived from salivary concentration data were 5.2 ± 0.4 mg/l, 1.9 ± 0.4 h and 3.6 ± 0.5 h, respectively, which were in agreement with those derived from plasma concentration data. The mean saliva-to-plasma concentration ratio (C(s)/C(p)) obtained after the administration of a single oral dose was 1.08 ± 0.05. This was both time-independent and concentration-independent, and it showed a certain relationship with age. A significant correlation was obtained between plasma and saliva concentrations (r = 0.768, p < 0.01). The coefficient of variation for the overall variability was approximately 30.0%. The present results indicate that the secretion of OFLX into saliva may be, at least, due to a passive diffusion mechanism, but a measurement of OFLX concentration in saliva as a guide to dose adjustment would be too wide at odds with plasma concentration to form the basis for a clinical decision.

AB - The simultaneous saliva and plasma ofloxacin (OFLX) concentrations in patients with respiratory tract infection were measured by a microbiological agar-well diffusion assay following a single oral administration of an OFLX preparation. The maximum concentration (C(max)), the time to reach that peak (t(max)) and the elimination half-life of OFLX derived from salivary concentration data were 5.2 ± 0.4 mg/l, 1.9 ± 0.4 h and 3.6 ± 0.5 h, respectively, which were in agreement with those derived from plasma concentration data. The mean saliva-to-plasma concentration ratio (C(s)/C(p)) obtained after the administration of a single oral dose was 1.08 ± 0.05. This was both time-independent and concentration-independent, and it showed a certain relationship with age. A significant correlation was obtained between plasma and saliva concentrations (r = 0.768, p < 0.01). The coefficient of variation for the overall variability was approximately 30.0%. The present results indicate that the secretion of OFLX into saliva may be, at least, due to a passive diffusion mechanism, but a measurement of OFLX concentration in saliva as a guide to dose adjustment would be too wide at odds with plasma concentration to form the basis for a clinical decision.

UR - http://www.scopus.com/inward/record.url?scp=0026544495&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026544495&partnerID=8YFLogxK

M3 - Article

VL - 30

SP - 46

EP - 50

JO - International Journal of Clinical Pharmacology and Therapeutics

JF - International Journal of Clinical Pharmacology and Therapeutics

SN - 0946-1965

IS - 2

ER -